Ralliant (NYSE:RAL) SVP Amir Kazmi Acquires 2,545 Shares

Ralliant Corporation (NYSE:RAL) SVP Amir Kazmi purchased 2,545 shares of the stock in a transaction on Friday, February 6th. The shares were purchased at an average price of $39.27 per share, for a total transaction of $99,942.15. Following the transaction, the senior vice president directly owned 39,699 shares of the company’s stock, valued at approximately $1,558,979.73. This represents a 6.85% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link.

Ralliant Trading Up 2.9%

Shares of RAL stock opened at $39.50 on Monday. The business has a 50-day moving average price of $51.52 and a two-hundred day moving average price of $46.72. Ralliant Corporation has a 12-month low of $37.27 and a 12-month high of $57.02. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38. The firm has a market cap of $4.46 billion and a P/E ratio of 31.10.

Ralliant (NYSE:RAL) last released its earnings results on Wednesday, February 4th. The company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.67 by $0.02. The business had revenue of $554.60 million for the quarter, compared to the consensus estimate of $543.04 million. The firm’s quarterly revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Shareholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a yield of 0.5%. Ralliant’s dividend payout ratio (DPR) is 15.75%.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RAL. Citigroup dropped their target price on shares of Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday. Morgan Stanley reissued an “overweight” rating and set a $45.00 price objective on shares of Ralliant in a research note on Friday. Weiss Ratings cut shares of Ralliant from a “hold (c)” rating to a “sell (d)” rating in a report on Thursday. Oppenheimer lowered their target price on shares of Ralliant from $60.00 to $50.00 and set an “outperform” rating for the company in a report on Friday. Finally, Barclays upped their price target on Ralliant from $59.00 to $60.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 7th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Ralliant has an average rating of “Moderate Buy” and a consensus target price of $51.30.

Hedge Funds Weigh In On Ralliant

A number of hedge funds have recently added to or reduced their stakes in the company. Allworth Financial LP lifted its stake in shares of Ralliant by 134.4% in the 4th quarter. Allworth Financial LP now owns 511 shares of the company’s stock worth $26,000 after purchasing an additional 293 shares during the period. Keybank National Association OH grew its position in shares of Ralliant by 1.6% during the 4th quarter. Keybank National Association OH now owns 19,667 shares of the company’s stock valued at $1,001,000 after acquiring an additional 305 shares during the period. Oregon Public Employees Retirement Fund increased its stake in shares of Ralliant by 1.6% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 25,800 shares of the company’s stock worth $1,313,000 after purchasing an additional 400 shares in the last quarter. Arizona State Retirement System raised its holdings in Ralliant by 1.2% in the 3rd quarter. Arizona State Retirement System now owns 33,566 shares of the company’s stock worth $1,468,000 after purchasing an additional 413 shares during the period. Finally, Danske Bank A S bought a new position in Ralliant in the 4th quarter worth $25,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.